{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-001119","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.905916+00:00","generated_at":"2026-05-15T23:58:57.455361+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"BioCryst reports record FY2025 operating profit; ORLADEYO rev $601.8M (+38%); maintains FY2026 guidance","bullets":["Full year 2025 GAAP operating profit $341.0M vs loss of $2.5M in 2024; total revenues $874.8M (incl $243.3M European sale) vs $450.7M.","Non-GAAP total revenues $592.9M (+45% YoY); non-GAAP operating profit $214.2M (+198%).","ORLADEYO net revenue $601.8M (+38% YoY; +43% ex-EU); FY2026 revenue guidance maintained at $625-645M.","Completed acquisition of Astria Therapeutics (navenibart); FDA approved ORLADEYO oral pellets for pediatric HAE.","Cash $337.5M at year-end; net cash generation $85.2M ex-debt payoff and EU sale proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-001119","json":"https://secwatch.observer/filing/0001171843-26-001119.json","markdown":"https://secwatch.observer/filing/0001171843-26-001119.md","text":"https://secwatch.observer/filing/0001171843-26-001119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/0001171843-26-001119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184326001119/f8k_022626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:58:57.455361+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}